New core-shell nanoparticules for the intravenous delivery of sirna to experimental thyroid papillary carcinoma

Pharmaceutical Research

Volumn 27, Issue 3, 2010, Pages 498-509

  De Martimprey, Henri ^a,b   Bertrand, Jean Rémi ^b   Malvy, Claude ^b   Couvreur, Patrick ^a   Vauthier, Christine ^a  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Nanoparticles; Poly(alkylcyanoacrylate); SiRNA; Thyroid papilloma carcinoma

Indexed keywords

BUCRILATE; CHITOSAN; CYANOACRYLATE DERIVATIVE; DRUG CARRIER; ISOHEXYLCYANOACRYLATE; NANOPARTICLE; POLOXAMER; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ADSORPTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; EMULSION; MATERIAL COATING; MOUSE; NANODEVICE; NONHUMAN; ONCOGENE; ONCOGENE PTC1; ONCOGENE RET; OXIDATION REDUCTION REACTION; POLYMERIZATION; PRIORITY JOURNAL; THYROID PAPILLARY CARCINOMA;

EID: 77949270747     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-009-0043-8     Document Type: Article

References (36)

1. A Kalota SE Shetzline AM Gewirtz 2004 Progress in the development of nucleic acid therapeutics for cancer Cancer Biol Ther 3 4 12 14726654 1:CAS:528:DC%2BD2cXjsVGiurw%3D
2. M Meyer E Wagner 2006 Recent developments in the application of plasmid DNA-based vectors and small interfering RNA therapeutics for cancer Hum Gene Ther 17 1062 1076 10.1089/hum.2006.17.1062 17032153 1:CAS:528:DC%2BD28Xht1Smt7rK (Pubitemid 44749709)
3. V Russ E Wagner 2007 Cell and tissue targeting of nucleic acids for cancer gene therapy Pharm Res 24 1047 1057 10.1007/s11095-006-9233-9 17387604 1:CAS:528:DC%2BD2sXlsVGnsr4%3D (Pubitemid 46798888)
4. AR de Fougerolles 2008 Delivery vehicles for small interfering RNA in vivo Hum Gene Ther 19 125 132 10.1089/hum.2008.928 18257677 1:CAS:528: DC%2BD1cXhvVyksLg%3D (Pubitemid 351278372)
5. N Shrivastava A Srivastava 2008 RNA interference: an emerging generation of biologicals Biotechnol J 3 339 353 10.1002/biot.200700215 18320564 1:CAS:528:DC%2BD1cXkt1Cls7Y%3D
6. G Hutvagner MJ Simard 2008 Argonaute proteins: key players in RNA silencing Nat Rev Mol Cell Biol 9 22 32 10.1038/nrm2321 18073770 1:CAS:528:DC%2BD2sXhsVKrsr3P
7. JR Bertrand M Pottier A Vekris P Opolon A Maksimenko C Malvy 2002 Comparison of antisense oligonucleotides and siRNA in cell culture and in vivo Biochem Biophys Res Commun 296 1000 1004 10.1016/S0006-291X(02)02013-2 12200148 1:CAS:528:DC%2BD38XmsV2ku7Y%3D
8. J Downward 2004 RNA interference BMJ 328 1245 1248 10.1136/bmj.328.7450. 1245 15155505 1:CAS:528:DC%2BD2cXntV2rtL0%3D
9. T Nguyen EM Menocal J Harborth JH Fruehauf 2008 RNAi therapeutics: an update on delivery Curr Opin Mol Ther 10 158 167 18386228 1:CAS:528: DC%2BD1cXlsVenur8%3D
10. KF Pirollo EH Chang 2008 Targeted delivery of small interfering RNA: approaching effective cancer therapies Cancer Res 68 1247 1250 10.1158/0008-5472.CAN-07-5810 18316585 1:CAS:528:DC%2BD1cXislagtLg%3D (Pubitemid 351346828)
11. E Fattal G Barratt 2009 Nanotechnologies and controlled release systems for the delivery of antisense oligonucleotides and small interfering RNA Br J Pharmacol 157 179 194 10.1111/j.1476-5381.2009.00148.x 19366348 1:CAS:528:DC%2BD1MXmsFWju7g%3D
12. HK de Wolf CJ Snel FJ Verbaan RM Schiffelers WE Hennink G Storm 2007 Effect of cationic carriers on the pharmacokinetics and tumor localization of nucleic acids after intravenous administration Int J Pharm 331 167 175 10.1016/j.ijpharm.2006.10.029 17134859 1:CAS:528:DC%2BD2sXhsFClsb4%3D (Pubitemid 46216670)
13. OB Garbuzenko M Saad S Betigeri M Zhang AA Vetcher VA Soldatenkov DC Reimer VP Pozharov T Minko 2009 Intratracheal versus intravenous liposomal delivery of siRNA, antisense oligonucleotides and anticancer drug Pharm Res 26 382 394 10.1007/s11095-008-9755-4 18958402 1:CAS:528:DC%2BD1cXht12ltb%2FO
14. J Am D Su O Che WS Li L Sun ZY Zhang B Yang F Xu 2009 Functional gene silencing mediated by chitosan/siRNA nanocomplexes Nanotechnology 20 405103 10.1088/0957-4484/20/40/405103 1:CAS:528:DC%2BD1MXht1GltrfK
15. KA Howard 2009 Delivery of RNA interference therapeutics using polycation-based nanoparticles Adv Drug Deliv Rev 61 710 720 10.1016/j.addr.2009.04.001 19356738 1:CAS:528:DC%2BD1MXmsFyns7k%3D
16. C Bouclier L Moine H Hillaireau V Marsaud E Connault P Opolon P Couvreur E Fattal JM Renoir 2008 Physicochemical characteristics and preliminary in vivo biological evaluation of nanocapsules loaded with siRNA targeting estrogen receptor alpha Biomacromolecules 9 2881 2890 10.1021/bm800664c 18788777 1:CAS:528:DC%2BD1cXhtFWmt7vJ
17. DW Bartlett ME Davis 2008 Impact of tumor-specific targeting and dosing schedule on tumor growth inhibition after intravenous administration of siRNA-containing nanoparticles Biotechnol Bioeng 99 975 985 10.1002/bit.21668 17929316 1:CAS:528:DC%2BD1cXit1Kqs70%3D (Pubitemid 351316639)
18. A Maksimenko V Polard M Villemeur H Elhamess P Couvreur JR Bertrand M Aboubakar M Gottikh C Malvy 2005 In vivo potentialities of EWS-Fli-1 targeted antisense oligonucleotides-nanospheres complexes Ann NY Acad Sci 1058 52 61 10.1196/annals.1359.010 16394125 1:CAS:528:DC%2BD28XislCrsbw%3D
19. H De Martimprey C Vauthier C Malvy P Couvreur 2009 Polymer nanocarriers for the delivery of small fragments of nucleic acids: oligonucleotides and siRNA Eur J Pharm Biopharm 71 490 504 10.1016/j.ejpb.2008.09.024 18977435 1:CAS:528:DC%2BD1MXisFWgt7Y%3D
20. XL Wang R Xu X Wu D Gillespie R Jensen ZR Lu 2009 Targeted systemic delivery of a therapeutic siRNA with a multifunctional carrier controls tumor proliferation in mice Mol Pharm 6 738 746 10.1021/mp800192d 19296675 1:CAS:528:DC%2BD1MXjtlOgtbo%3D
21. N Toub JR Bertrand A Tamaddon H Elhamess H Hillaireau A Maksimenko J Maccario C Malvy E Fattal P Couvreur 2006 Efficacy of siRNA nanocapsules targeted against the EWS-Fli1 oncogene in Ewing sarcoma Pharm Res 23 892 900 10.1007/s11095-006-9901-9 16715379 1:CAS:528:DC%2BD28XkslKjtrw%3D (Pubitemid 43781397)
22. H Elhamess JR Bertrand J Maccario A Maksimenko C Malvy 2009 Antitumor vectorized oligonucleotides in a model of ewing sarcoma: unexpected role of nanoparticles Oligonucleotides 19 255 264 10.1089/oli.2009.0197 19732024 1:CAS:528:DC%2BD1MXhtFCjtb3E
23. H de Martimprey JR Bertrand A Fusco M Santoro P Couvreur C Vauthier C Malvy 2008 siRNA nanoformulation against the ret/PTC1 junction oncogene is efficient in an in vivo model of papillary thyroid carcinoma Nucleic Acids Res 36 1 e2 10.1093/nar/gkm1094 10.1093/nar/gkm1094 18079153 1:CAS:528: DC%2BD1cXpt12rtg%3D%3D
24. I Bertholon S Lesieur D Labarre M Besnard C Vauthier 2006 Characterization of dextran-poly(isobutylcyanoacrylate) copolymers obtained by redox radical and anionic emulsion polymerization Macromolecules 39 3559 3567 10.1021/ma060338z 1:CAS:528:DC%2BD28Xjtlartbw%3D (Pubitemid 43798234)
25. I Bertholon C Vauthier D Labarre 2006 Complement activation by core-shell poly(isobutylcyanoacrylate)-polysaccharide nanoparticles: influences of surface morphology, length, and type of polysaccharide Pharm Res 23 1313 1323 10.1007/s11095-006-0069-0 16715369 1:CAS:528:DC%2BD28XmtFCnsbw%3D (Pubitemid 43946153)
26. A Vonarbourg C Passirani P Saulnier JP Benoit 2006 Parameters influencing the stealthiness of colloidal drug delivery systems Biomaterials 27 4356 4373 10.1016/j.biomaterials.2006.03.039 16650890 1:CAS:528:DC%2BD28XksFyns7g%3D (Pubitemid 43674179)
27. C Passirani G Barratt JP Devissaguet D Labarre 1998 Long-circulating nanoparticles bearing heparin or dextran covalently bound to poly(methyl methacrylate) Pharm Res 15 1046 1050 10.1023/A:1011930127562 9688058 1:CAS:528:DyaK1cXkvVWgtbc%3D (Pubitemid 28356921)
28. P Decuzzi R Pasqualini W Arap M Ferrari 2009 Intravascular delivery of particulate systems: does geometry really matter? Pharm Res 26 235 243 10.1007/s11095-008-9697-x 18712584 1:CAS:528:DC%2BD1cXhsFSjsr7P
29. I Bravo-Osuna G Ponchel C Vauthier 2007 Tuning of shell and core characteristics of chitosan-decorated acrylic nanoparticles Eur J Pharm Sci 30 143 154 10.1016/j.ejps.2006.10.007 17157487 1:CAS:528:DC%2BD2sXpvVyitQ%3D%3D (Pubitemid 46149279)
30. T Mosmann 1983 Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays J Immunol Meth 65 55 63 10.1016/0022-1759(83)90303-4 1:STN:280:DyaL2c%2FovFSmtw%3D%3D
31. C Vauthier C Schmidt P Couvreur 1999 Measurement of the density of polymeric nanoparticulate drug carriers made of poly(alkylcyanoacrylate) and poly(lactic acid) derivatives J Nanoparticle Res 1 411 418 10.1023/A: 1010031605547 1:CAS:528:DC%2BD3cXpvVCkug%3D%3D
32. IY Kim MK Yoo BC Kim SK Kim HC Lee CS Cho 2006 Preparation of semi-interpenetrating polymer networks composed of chitosan and poloxamer Int J Biol Macromol 38 51 58 10.1016/j.ijbiomac.2005.12.020 16442610 1:CAS:528:DC%2BD28XitVejs78%3D (Pubitemid 43324732)
33. C Chauvierre L Leclerc D Labarre M Appel MC Marden P Couvreur C Vauthier 2007 Enhancing the tolerance of poly(alkylcyanoacrylate) nanoparticles with surface modular design Int J Pharm 338 327 332 10.1016/j.ijpharm.2007.01.034 17324536 1:CAS:528:DC%2BD2sXlslWgsLY%3D (Pubitemid 46795462)
34. F Nemati C Dubernet A Colin de Verdière MF Poupon L Treupel-Acar F Puisieux P Couvreur 1994 Some parameters influencing cytotoxicity of free doxorubicin loaded nanoparticles in sensitive and multidrug resistant leucemic murine cells: incubation time, number of nanoparticles per cell Int J Pharm 102 55 62 10.1016/0378-5173(94)90039-6 1:CAS:528:DyaK2cXhsVeqtr0%3D (Pubitemid 124013789)
35. V Mailänder K Landfester 2009 Interaction of nanoparticles with cells Biomacromolecules 10 2379 2400 10.1021/bm900266r 19637907 1:CAS:528:DC%2BD1MXptV2nsLY%3D
36. AK Iyer G Khaled J Fang H Maeda 2006 Exploiting the enhanced permeability and retention effect for tumor targeting Drug Discov Today 11 812 818 10.1016/j.drudis.2006.07.005 16935749 1:CAS:528:DC%2BD28XoslOgtLo%3D (Pubitemid 44280021)